Cyclin-dependent kinase 2 (CDK2)
Cyclin-dependent kinase 2 (CDK2) is a serine/threonine protein kinase that functions as a core regulator of cell-cycle progression.
Cyclin-dependent kinase 2 (CDK2) is a serine/threonine protein kinase that functions as a core regulator of cell-cycle progression. In normal biology, CDK2 acts in concert with cyclins to control transitions through the G1/S boundary and S phase, thereby coordinating DNA replication and cell proliferation. Because of this central role in cell-cycle control, CDK2 is widely studied in oncology and drug discovery as a target for suppressing uncontrolled tumor growth.
In recent biomedical research, CDK2 has been especially relevant in cancers that evade Cdk4/6 inhibitor therapy or show CCNE1 amplification, both of which can indicate dependence on CDK2-driven cell-cycle signaling. It is also frequently evaluated alongside related kinases such as cyclin-dependent kinase 6 (CDK6), cyclin-dependent kinase 1, and Aurora kinase A (AURKA), as well as pathway-associated proteins including BCL2 apoptosis regulator, caspase-3, and Mki67, to understand how cell-cycle arrest, apoptosis, and proliferation are altered by candidate therapies.
Where the papers sit
12 papers from the last 6 months study Cyclin-dependent kinase 2 (CDK2) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 human data · 9 preclinical · 1 unclassified
Themes 3 themes
-
Dual CDK2 Inhibitor Discovery
Pyrimidine and heterocyclic scaffolds are being optimized as selective or dual CDK2 inhibitors, often with EGFR or TrkA activity. Docking, dynamics and network pharmacology guide binding hypotheses and scaffold refinement. Antiproliferative assays and mechanistic studies recur, but most evidence remains early-stage and compound-focused. Selectivity, cellular target engagement and in vivo efficacy remain open.
5 papers · 41.7%
-
Cancer Cell-Cycle Signaling
CDK2-driven cell-cycle control is being linked to transcriptional regulation, tumour progression and treatment response across cervical and liver cancer models. Cyclin E-CDK2 and BRD4 connect proliferation to cancer-cell transcription and immunotherapy response, while RSRC1 tracks p53/CDK2-associated signaling. PTEN/AKT/p53 pathway disruption and pifithrin-α-sensitive effects recur with cell-cycle phenotypes. Small-molecule hybrids and gene-silencing studies support CDK2 as a therapeutic and biomarker target, but clinical validation remains open.
4 papers · 33.3%
-
Others — CDK2 and Biomaterial Research
Selective CDK2 degradation is emerging alongside conventional inhibitor design, using noncanonical recruitment and Cereblon (CRBN)-based approaches. Molecular dynamics and pharmacokinetic analysis are being used to improve selectivity and exposure. The cluster also includes antibacterial chitosan cryogel work, which does not share a clear CDK2 question. No unified therapeutic direction can be inferred.
3 papers · 25%
Papers
The 12 papers from the last 6 months that study Cyclin-dependent kinase 2 (CDK2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Dual CDK2 Inhibitor Discovery (5)
- Discovery of pyrimidine-based dual CDK2/TrkA inhibitors: Synthesis, antiproliferative activity, and mechanistic insights. Bioorganic chemistry · 26 Sept 2026 PMID 42800165
- Using network pharmacology and structural biology to elucidate the molecular mechanism by which Macrolactin A protects against aphids. Pesticide biochemistry and physiology · 23 Jul 2026 PMID 42493046
- Network pharmacology, molecular docking, and dynamics simulation of 7-phenyl-5-(p-tolyl)pyrido[2,3-d] pyrimidine-4-amine as anticancer agents with multitarget inhibitory action. Computers in biology and medicine · 3 Jun 2026 PMID 42235269
- Design, synthesis, anticancer activity, and mechanistic investigation of 4,5,6,7-tetrahydrobenzo[b]thiophene carboxamides as CDK-2 inhibitors: in vitro and in silico DFT and molecular docking study. Journal of enzyme inhibition and medicinal chemistry · 29 May 2026 PMID 42210722
- Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
Cancer Cell-Cycle Signaling (4)
- RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling. European journal of pharmacology · 19 Sept 2026 PMID 42762908
- Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4. Molecular cell · 2 Sept 2026 PMID 42685699
- Fluorinated isoindolinone-amino acid hybrids possessing antiproliferative and antitumor activity in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480152
- CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. Human cell · 1 Jul 2026 PMID 42384246
Others — CDK2 and Biomaterial Research (3)
- Selective CDK2 Degradation via Noncanonical Recruitment. Journal of medicinal chemistry · 23 Jun 2026 PMID 42334090
- Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors. Journal of medicinal chemistry · 22 Jun 2026 PMID 42328801
- Phenothiazine dye-loaded chitosan cryogels as multifunctional antibacterial wound dressings. Scientific reports · 21 Jun 2026 PMID 42324341
By study type
Human data, design not indexed (2)
- Phenothiazine dye-loaded chitosan cryogels as multifunctional antibacterial wound dressings. Scientific reports · 21 Jun 2026 PMID 42324341
- Network pharmacology, molecular docking, and dynamics simulation of 7-phenyl-5-(p-tolyl)pyrido[2,3-d] pyrimidine-4-amine as anticancer agents with multitarget inhibitory action. Computers in biology and medicine · 3 Jun 2026 PMID 42235269
Preclinical: animal, cell and lab studies (9)
- Discovery of pyrimidine-based dual CDK2/TrkA inhibitors: Synthesis, antiproliferative activity, and mechanistic insights. Bioorganic chemistry · 26 Sept 2026 PMID 42800165
- RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling. European journal of pharmacology · 19 Sept 2026 PMID 42762908
- Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4. Molecular cell · 2 Sept 2026 PMID 42685699
- Using network pharmacology and structural biology to elucidate the molecular mechanism by which Macrolactin A protects against aphids. Pesticide biochemistry and physiology · 23 Jul 2026 PMID 42493046
- Fluorinated isoindolinone-amino acid hybrids possessing antiproliferative and antitumor activity in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480152
- CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. Human cell · 1 Jul 2026 PMID 42384246
- Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors. Journal of medicinal chemistry · 22 Jun 2026 PMID 42328801
- Design, synthesis, anticancer activity, and mechanistic investigation of 4,5,6,7-tetrahydrobenzo[b]thiophene carboxamides as CDK-2 inhibitors: in vitro and in silico DFT and molecular docking study. Journal of enzyme inhibition and medicinal chemistry · 29 May 2026 PMID 42210722
- Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
Unclassified: not yet indexed with MeSH (1)
- Selective CDK2 Degradation via Noncanonical Recruitment. Journal of medicinal chemistry · 23 Jun 2026 PMID 42334090
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-28. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.